semaglutide clinical trials SELECT Trial SELECT Trial

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026

In stock for treating type 2 diabetes and aiding weight loss

Discover which medication helps treat obesity and how to safely order weight management treatments online.

Chromium (as Chromium Picolinate) 1000 mcg (2,857% DV)

Cloudy urine can be caused by a number of medical conditions, including dehydration, a urinary tract infection, sexually transmitted infections, kidney stones, diabetes, and more